The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for approximately 40% of familial ALS cases and 25% of familial FTD cases. This pathogenic expansion leads to three distinct disease mechanisms: RNA foci formation, dipeptide repeat protein (DPR) toxicity, and reduced C9orf72 protein expression.
The C9orf72 gene contains a hexanucleotide repeat (GGGGCC) in its first intron. Normal individuals have 2-30 repeats, while affected individuals have hundreds to thousands of repeats. This expansion causes disease through three interconnected mechanisms:
- Toxic RNA foci: Repeat-containing RNA sequesters RNA-binding proteins
- Dipeptide repeat proteins: Translation of the repeat produces toxic DPRs (GA, GP, GR, PA, PR)
- Loss of function: Reduced C9orf72 protein expression affects lysosomal/autophagic function
flowchart TD
A["C9orf72 Hexanucleotide<br>Repeat Expansion → BRepeat RNA<br>Transcript → "]
B --> C["RNA Foci Formation"]
C --> D["RNA-Binding Protein<br>Sequestration → "]
B --> E["Non-ATG Translation"]
E --> FDipeptide Repeat<br>Proteins (DPRs)
F --> G["GA DPRs<br>Neurotoxic → "]
F --> H["GP DPRs<br>Neurotoxic → "]
F --> I["GR DPRs<br>Stress Granules → "]
F --> J["PA/PR DPRs<br>Aggregation → "]
G --> K["Neuronal Dysfunction"]
H --> K
I --> K
J --> K
K --> L["Neuronal Death"]
A --> M["Reduced C9orf72<br>Protein Expression → "]
M --> N["Autophagy/Lysosome<br>Dysfunction → "]
N --> L
D --> O["RNA Processing<br>Defects → "]
O --> K
style G fill:#ff6b6b,color:#fff
style L fill:#ee5a5a,color:#fff
¶ 1. Genetics and Normal Function
C9orf72 Gene Structure:
- Located on chromosome 9p21
- Three transcripts: V1 (full length), V2 (short), V3
- Encodes a DENN domain protein
Normal C9orf72 Function:
- Guanine nucleotide exchange factor (GEF) for Rab GTPases
- Regulates autophagy-lysosome pathway
- Involved in endosomal trafficking
- Expressed in neurons, microglia, astrocytes
Normal vs Pathological:
- Normal: 2-30 repeats
- Intermediate: 30-50 repeats (risk uncertain)
- Pathological: >50 repeats (typically 100s-1000s)
Repeat RNA Properties:
- Forms G-quadruplex structures
- Bidirectional transcription (sense and antisense foci)
- Nuclear RNA foci accumulation
The expanded repeat RNA forms nuclear RNA foci that sequester essential RNA-binding proteins:
| hnRNPs | RNA splicing | Splicing defects |
| Pur-α | RNA transport | Transport disruption |
| TDP-43 | RNA processing | TDP-43 mislocalization |
| ADAR | RNA editing | Editing alterations |
Five DPRs are produced through non-ATG (RAN) translation:
| DPR |
Sequence |
Primary Effects |
| poly-GA |
Gly-Ala |
Aggregate formation, proteostasis disruption |
| poly-GP |
Gly-Pro |
Less toxic, may have protective effects |
| poly-GR |
Gly-Arg |
Stress granule formation, nucleolar stress |
| poly-PA |
Pro-Ala |
Aggregation, synaptic dysfunction |
| poly-PR |
Pro-Arg |
Nuclear import disruption, nucleolar stress |
The expansion also reduces C9orf72 protein expression:
- Promoter hypermethylation
- Reduced transcription
- Haploinsufficiency
Consequences:
- Autophagic-lysosomal dysfunction
- Impaired endosomal trafficking
- Microglial activation abnormalities
- Sequestration of RNA-binding proteins
- Disrupted RNA splicing
- Altered RNA transport
- Nuclear export defects
- GA aggregates: Impair proteasome function
- GR/PR toxicity: Stress granule persistence, nucleolar stress
- Synaptic dysfunction: Impaired neurotransmitter release
- Reduced lysosomal function
- Impaired protein clearance
- Accumulation of damaged organelles
¶ Genetic and Clinical Features
- Autosomal dominant
- Reduced penetrance (age-dependent)
- Anticipation (earlier onset in successive generations)
- ALS (classic, bulbar, limb)
- FTD (behavioral variant, primary progressive aphasia)
- ALS-FTD overlap
- Some cases: parkinsonism, psychiatric symptoms
- Reduced C9orf72 expression in blood/CSF
- RNA foci in patient cells
- DPR proteins in CSF
- TDP-43 pathology (secondary)
- Antisense oligonucleotides (ASOs) targeting C9orf72 repeat
- Small molecules binding G-quadruplex
- RNA-binding protein sequestrations
- DPR aggregation inhibitors
- Autophagy enhancers
- Proteasome modulators
- Gene therapy to restore C9orf72 expression
- Autophagy enhancers
- Lysosomal function modulators
| Trial |
Target |
Status |
Company |
| BIIB078 |
C9orf72 repeat RNA |
Completed |
Biogen |
| WVE-004 |
C9orf72 DPRs |
Phase 1/2 |
Wave Life Sciences |
| ION363 |
C9orf72 |
Phase 1 |
Ionis/Roche |
- AAV-mediated gene silencing
- CRISPR-based editing (in development)
- Viral vector-delivered RNAi
- G-quadruplex stabilizers (toxicity concerns)
- DPR aggregation inhibitors
- Autophagy enhancers (trehalose, rapamycin)
Based on recent research, emerging targets include:
- Nucleocytoplastic transport: Nup98, RanGAP modulators
- Stress granule dynamics: GSK3β inhibitors, SG dispersal compounds
- DNA damage repair: ATM/ATR inhibitors
- Neuroinflammation: Microglial modulators
| Biomarker |
Source |
ALS |
FTD |
Clinical Utility |
| NfL |
CSF/Plasma |
Elevated |
Variable |
Progression marker |
| pTDP-43 |
CSF |
Elevated |
Elevated |
Diagnostic |
| DPRs |
CSF |
Detectable |
Detectable |
Target engagement |
| C9orf72 expression |
Blood |
Reduced |
Reduced |
Genotype confirmation |
- Genetic testing: Gold standard for diagnosis
- RNA foci: Detectible in patient cells
- DPR proteins: CSF-based detection in development
The study of C9Orf72 Hexanucleotide Repeat Expansion Pathway In Als And Ftd has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this mechanism.
The C9orf72 hexanucleotide repeat expansion can cause either ALS, FTD, or both (ALS-FTD) in different individuals, even within the same family. This phenotypic variability represents a major unresolved question in the field. Multiple factors contribute to this divergence.
The methylation status of the C9orf72 repeat region correlates with phenotype:
- Hypomethylation: More common in ALS patients, associated with higher repeat instability
- Hypermethylation: More common in FTD patients, associated with transcriptional silencing
- Intermediate methylation: Often seen in ALS-FTD overlap cases
Alternative splicing and RNA editing patterns differ between ALS and FTD patients:
- ALS: Preferential expression of toxic RNA foci
- FTD: More DPR accumulation due to translation efficiency
¶ Repeat Length and Structure
While both ALS and FTD patients carry large expansions (>100 repeats), subtle differences exist:
- Very large repeats (>1000): More common in ALS cases
- Intermediate-large repeats (100-500): More common in FTD cases
Rare interruptions in the pure GGGGCC repeat sequence can modify toxicity:
- Pure repeats: Full toxic gain-of-function
- Interrupted repeats: Attenuated toxicity, more likely FTD phenotype
Different brain regions show vulnerability depending on phenotype:
- ALS-vulnerable regions: Motor cortex, spinal cord motor neurons, bulbar nuclei
- FTD-vulnerable regions: Frontal and anterior temporal lobes
- Overlap: Anterior cingulate, insula, thalamus
- ALS with C9orf72: Motor neuron loss, Bunina bodies, TDP-43 inclusions
- FTD with C9orf72: Frontotemporal atrophy, TDP-43 type B inclusions
- ALS-FTD: Combined features with TDP-43 type A/B
Age at symptom onset shows phenotypic correlation:
- ALS: Mean onset 54-56 years
- FTD: Mean onset 58-62 years
- Earlier onset: More likely to present as ALS
- Later onset: More likely to present as FTD
- Progressive muscle weakness and atrophy
- Bulbar dysfunction (dysarthria, dysphagia)
- Respiratory involvement
- Fasciculations and cramps
- FTD presentation: Behavioral variant FTD (disinhibition, apathy)
- ALS-FTD: Combined motor and cognitive decline
- Cognitive reserve: May delay onset of cognitive symptoms
Epidemiological studies show:
- Males: Slightly higher likelihood of ALS phenotype
- Females: Slightly higher likelihood of FTD phenotype
- Overall: No strong sex bias in C9orf72 carriers
Understanding phenotype divergence has therapeutic implications:
- RNA foci reduction: Antisense oligonucleotides targeting repeat RNA
- DPR sequestration: Small molecules blocking DPR aggregation
- Motor neuron protection: Neurotrophic factors, anti-apoptotic agents
- TDP-43 modulation: Strategies to prevent TDP-43 mislocalization
- Frontal circuit protection: Synaptic stabilizers, neuroinflammation reduction
- Behavioral modification: Targeted interventions for disinhibition
- Gene silencing: ASOs reducing C9orf72 expression
- Protein restoration: Enhancing lysosomal function
- General neuroprotection: Anti-oxidant, anti-inflammatory approaches
Phenotype-specific biomarkers are being developed:
- Blood DPR levels: Correlate with disease progression
- Neurofilament light chain: Higher in ALS than FTD
- CSF TDP-43: Different isoforms in ALS vs FTD
- Imaging markers: Regional atrophy patterns
The phenotypic divergence in C9orf72-associated disease reflects the complex interplay of genetic modifiers, epigenetic changes, repeat architecture, and regional brain vulnerability. While significant progress has been made in understanding these factors, predicting phenotype in individual patients remains challenging. Continued research into the mechanisms underlying this variability will be essential for developing personalized therapeutic approaches.